stockportfolio.pro
STERIS plc (STE)
Healthcare · Medical Devices · NYSE
STERIS plc revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.61B | $2.62B | $2.78B | $3.03B | $3.11B | $4.22B | $4.96B | $5.50B | $5.46B | $5.94B |
| Gross profit | $1.03B | $1.09B | $1.17B | $1.32B | $1.34B | $1.88B | $1.98B | $2.22B | $2.40B | $2.63B |
| Net income | $109.97M | $290.92M | $303.72M | $407.66M | $397.40M | $243.89M | $107.03M | $378.20M | $614.64M | $782.30M |
| Net margin | 4.2% | 11.1% | 10.9% | 13.5% | 12.8% | 5.8% | 2.2% | 6.9% | 11.3% | 13.2% |
Source: STERIS plc SEC filings (10-K).
What growth is priced into STE stock?
At today's market cap of $20.78B, STERIS plc is priced for free-cash-flow growth of about 8.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $972.40M from the FY ending 2026-03-31). For comparison, free cash flow actually grew 16.6%/yr over the last five fiscal years and revenue 13.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 10 years of STERIS plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track STE in your portfolio →
STERIS plc financial history by metric
About STERIS plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
STERIS plc — frequently asked questions
What is STERIS plc's revenue?
STERIS plc (STE) reported revenue of $5.94B for fiscal year 2026, up 8.7% from the prior year, according to its SEC filings.
Is STERIS plc profitable?
Yes. STE earned net income of $782.30M in fiscal 2026, a net margin of 13.2%.
What is STE's P/E ratio?
STERIS plc trades at a price-to-earnings ratio of about 26.8 based on the latest data in our nightly-refreshed cache.
How fast is STERIS plc growing?
STE's revenue grew at roughly 13.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does STERIS plc have?
As of fiscal year 2026, STE carried roughly $1.93B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is STERIS plc's gross margin?
STE's gross margin was 44.2% in fiscal 2026 — gross profit of $2.63B on revenue of $5.94B.
What is STERIS plc's market cap?
STERIS plc (STE) has a market capitalization of about $20.78B, based on the latest data in our nightly-refreshed cache.
When does STERIS plc's fiscal year end?
STE's fiscal year ends in March. Its most recent annual filing covers the fiscal year ending 2026-03-31.
What growth is priced into STE stock?
At today's market cap of $20.78B, STERIS plc is priced for free-cash-flow growth of about 8.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $972.40M from the FY ending 2026-03-31). For comparison, free cash flow actually grew 16.6%/yr over the last five fiscal years and revenue 13.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from STERIS plc's official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.